Panel Discussion: Breaking the Efficacy Ceiling with Strategies to Enhance Depth & Durability in Next- Generation T-Cell Engagers
- Analyzing recent clinical readouts to understand why safety optimized molecules often encounter an efficacy plateau and identifying the biological drivers behind limited therapeutic depth
- Evaluating the integration of signal 2 to overcome the efficacy ceiling, moving from transient T-cell activation to sustained, robust anti-tumor responses
- Utilizing advanced biomarker strategies to identify patientspecific T-cell characterises and TME features that predict which individuals will achieve durable remissions